Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Celsion Corp

(NASDAQ: CLSN)
Add to Portfolio
+0.03 (+1.78%)
as of Oct 18, 2019

Last 1.72
Change +0.03 (+1.78%)
Open 1.70
Prev. Close 1.69
Today's Range
1.69
1.76
52wk Range
1.35
2.66
Volume 84,400
Avg Volume 124,080
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
CLSN +1.78% +2.07% -34.66%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS -0.35
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 36,150
Weighted Alpha -25.30
Standard Deviation +0.57
Profit Margin N/A
Beta 1.90

Growth Rates

YTD +22.34%
1-Year -30.72%
3-Year -89.38%
5-Year -95.24%
10-Year -99.13%

Opinion

Sell Hold Buy

Recent Headlines

Celsion Strengthens Its 2019 Balance Sheet with the

GlobeNewswire via COMTEX - Tue Oct 01, 08:07AM EDT
$2 Million in Additional NOL Sales are Available to the Company in 2020(full story)
CLSN: 1.72 (+0.03)

Celsion to Present at the Chardan 3rd Annual Genetic

GlobeNewswire via COMTEX - Mon Sep 30, 02:30PM EDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer (full story)
CLSN: 1.72 (+0.03)

Celsion Co-sponsors Hepatocellular Carcinoma Symposium

GlobeNewswire via COMTEX - Mon Sep 23, 08:02AM EDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13 Annual Conference of the International Liver Cancer Associa(full story)
CLSN: 1.72 (+0.03)

Celsion Announces Publication of Findings from

GlobeNewswire via COMTEX - Tue Aug 27, 08:01AM EDT
Data show overall survival improvement of 22.5 months with ThermoDox plus RFA of 45 minutes or longer(full story)
CLSN: 1.72 (+0.03)

Celsion Corporation Reports Second Quarter 2019

GlobeNewswire via COMTEX - Wed Aug 14, 04:30PM EDT
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October(full story)
CLSN: 1.72 (+0.03)